Chin Circul J:NT-proBNP有助于无心衰心梗患者危险分层

2017-04-01 卢芳 中国循环杂志

对于左心室射血分数正常,且无明显舒张性心力衰竭症状的急性ST段抬高型心肌梗死(STEMI)患者而言,血浆氨基末端B 型利钠肽原(NT-proBNP)浓度有何意义?郑州大学第二附属医院赵玉兰、江冠颖等进行的研究显示,NT-proBNP在一定程度上可以反映STEMI患者的冠脉狭窄严重程度,对三支血管病变及前降支病变有一定预见作用,临床常规检测STEMI患者NT-proBNP浓度有助于其临床诊疗及危险分

对于左心室射血分数正常,且无明显舒张性心力衰竭症状的急性ST段抬高型心肌梗死(STEMI)患者而言,血浆氨基末端B 型利钠肽原(NT-proBNP)浓度有何意义?

郑州大学第二附属医院赵玉兰、江冠颖等进行的研究显示,NT-proBNP在一定程度上可以反映STEMI患者的冠脉狭窄严重程度,对三支血管病变及前降支病变有一定预见作用,临床常规检测STEMI患者NT-proBNP浓度有助于其临床诊疗及危险分层。

研究显示,随着患者冠脉病变严重程度的增加及病变支数的增加,NT-proBNP浓度显着增加。比如研究显示,左前降支为罪犯血管者血浆NT-proBNP浓度较罪犯血管为非左前降支者显着增加;评估冠脉病变狭窄严重程度的Gensini 积分与NT-proBNP浓度呈正相关。


研究者指出,即使患者血流动力学稳定,心肌细胞缺血损伤及室壁张力增加即可刺激心肌细胞分泌NT-proBNP,故急性冠脉综合征患者无论心功能正常与否均可使血浆NT-proBNP增加。

该研究共纳入STEMI患者280例,并在入院24小时内检测了血浆NT-proBNP浓度,同时应用Gensini评分系统进行了不同分组,以及对冠脉病变支数也进行了分组,以期观察血浆NT-proBNP浓度与冠脉病变关系。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049460, encodeId=77f220494606a, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 28 12:10:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720508, encodeId=48681e205084a, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Wed Sep 06 13:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289296, encodeId=edc5128929647, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290335, encodeId=fe0512903356e, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601839, encodeId=515f160183916, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049460, encodeId=77f220494606a, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 28 12:10:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720508, encodeId=48681e205084a, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Wed Sep 06 13:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289296, encodeId=edc5128929647, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290335, encodeId=fe0512903356e, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601839, encodeId=515f160183916, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049460, encodeId=77f220494606a, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 28 12:10:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720508, encodeId=48681e205084a, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Wed Sep 06 13:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289296, encodeId=edc5128929647, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290335, encodeId=fe0512903356e, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601839, encodeId=515f160183916, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 huiwelcome
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049460, encodeId=77f220494606a, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 28 12:10:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720508, encodeId=48681e205084a, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Wed Sep 06 13:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289296, encodeId=edc5128929647, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290335, encodeId=fe0512903356e, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601839, encodeId=515f160183916, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 mjldent
  5. [GetPortalCommentsPageByObjectIdResponse(id=2049460, encodeId=77f220494606a, content=<a href='/topic/show?id=5c2e5106290' target=_blank style='color:#2F92EE;'>#心梗患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51062, encryptionId=5c2e5106290, topicName=心梗患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e6a1280, createdName=zhanglin3079, createdTime=Sun Jan 28 12:10:00 CST 2018, time=2018-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1720508, encodeId=48681e205084a, content=<a href='/topic/show?id=09bf36e741d' target=_blank style='color:#2F92EE;'>#危险分层#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36774, encryptionId=09bf36e741d, topicName=危险分层)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1d5032846700, createdName=tidiq, createdTime=Wed Sep 06 13:10:00 CST 2017, time=2017-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1289296, encodeId=edc5128929647, content=<a href='/topic/show?id=ede136018b' target=_blank style='color:#2F92EE;'>#BNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3601, encryptionId=ede136018b, topicName=BNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1290335, encodeId=fe0512903356e, content=<a href='/topic/show?id=f6e513111bc' target=_blank style='color:#2F92EE;'>#NT-proBNP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13111, encryptionId=f6e513111bc, topicName=NT-proBNP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5662228, createdName=mjldent, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1601839, encodeId=515f160183916, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Mon Apr 03 09:10:00 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 sunylz

相关资讯

中国循环杂志:阜外学者发现,房颤并非心脏再同步化治疗患者心衰再住院和死亡的独立危险因素

近期,阜外医院刘尚雨等在本刊发文称,尽管合并房颤的心脏再同步化治疗(CRT)患者心衰再住院率增加,但房颤并非该类患者心衰再住院和全因死亡的独立危险因素。该研究回顾性收集2010-01 至2014-12 于阜外医院心律失常中心接受首次接受CRT的258 例患者临床资料,根据是否合并房颤,将患者分为房颤组和无房颤组。中位随访22 个月,死亡33 例(12.8%),心脏移植5例(1.9%),心衰再住院7

外科病房的护士遇到急性心衰患者怎么办

外科护士还是要注意多对特殊患者进行巡视,多观察病情,了解患者的异常情况,及时通知医生,做医生的好帮手,积极参与抢救。心衰是指由于心脏的收缩功能和(或)舒张功能发生障碍,不能将静脉回心血量充分排出心脏,导致静脉系统血液淤积,动脉系统血液灌注不足,从而引起心脏循环障碍症候群,此种障碍症候群集中表现为肺淤血、腔静脉淤血。其中绝大多数的心力衰竭都是以左心衰竭开始的,即首先表现为肺循环淤血。急性心衰的临床表

Chin Circul J:阜外医院华伟和樊晓寒点评四种新型心衰器械治疗:药物联合器械植入是未来方向

治疗心衰很有挑战,阜外医院华伟、樊晓寒指出,优化药物联合个体化的器械植入将成为未来心力衰竭治疗方向,并就当前器械治疗慢性心衰的新进展在本刊进行了阐述。心脏再同步化治疗:心室多位点起搏技术将有更好应用前景大量临床试验证明,心脏再同步化治疗(CRT)可减少中重度心衰患者再入院率、逆转心室重构、降低死亡率,并且相关指南也做了明确推荐。近年来,CRT技术的新进展主要是左心室四极导线和左心室多位点起搏技术(

BMJ:社区获得性肺炎与心衰的相关性 不可不知

社区获得性肺炎是与高发病率和死亡率相关的常见疾病,不考虑年龄。此病是美国第七大主要死因。2017年2月,发表在《BMJ》的一项由加拿大科学家进行的10年随访的前瞻性对照研究考察了社会获得性肺炎后心衰风险。请看本期多学科讨论组临床药师各抒己见为您梳理本文看点——目的:旨在确定社区获得性肺炎对各年龄层的受影响患者和各感染严重程度患者的心衰发生率的归因风险。设计:队列研究。地点:加拿大2000~2002

心力衰竭的春天因你来,全新心力衰竭指南集锦!

一、急性心力衰竭  2016 成人急性心力衰竭护理实践指南 本指南基于目前可获得的最佳临床证据制定而成,涵盖了急性心力衰竭护理的干预措施,引用的大部分证据都与急性心力衰竭发病后紧急救治有关,是急诊室、监护室、病房、社区护理人员开展急性心力衰竭管理的临床决策参考工具。可用于:①提供临床护理的推荐意见;②制定循证护理实践方案;③制定护理实践的评价标准;④规范培训护理人员。 二、慢性

Am J Epidemiol:流感导致的住院率及心血管疾病现状调查

最近,Am J Epidemiol杂志中一篇文章报道了流感的住院率,及流感相关的心血管疾病发生的比例。我们都知道,流感是一种患病率及死亡率均较高的疾病。该文章主要针对热带地区的新加坡人群展开了调查,旨在考察流感相关的住院率及心血管疾病(CVD)发生率。选取国家住院数据库中2010-2014年间的,缺血性心肌病(IHD)、充血性心衰(CHF)、以及所有的CVD患者作为研究对象。社区诊断的流感阳性的流